Stage
No active trials
Next date
None yet
Trials
0 active
4 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “ADG106 injection, intravenous infusion, is administered as body weight every 3 weeks for 21 days as a cycle”In the company’s words, NCT04775680 on ClinicalTrials.gov
- Tested for
- Solid Tumor (2 trials), Non Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Solid Tumors, Non-Hodgkin Lymphoma, Advanced/Metastatic Solid Tumors
- Main trialPhase 1/2
- “This is a Multicenter, Open-Label, Phase Ib/II Study of ADG106 in Combination with PD-1 Antibody in Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma. The primary objective of Phase Ib: To evaluate the maximum tolerated dosage (MTD) of ADG106 in combination with PD-1 antibody in advanced solid tumors and relapsed/refractory non-Hodgkin lymphoma, and to determine the recommended phase II clinical studies dosage (RP2D).”In the company’s words, NCT04775680 on ClinicalTrials.gov
Other drugs for Solid Tumor
- AvelumabEMD Serono Research & Development Institute, Inc. · Phase 3
- AlectinibRoche · Phase 3
- AtezolizumabRoche · Phase 3
- AU-011Aura Biosciences · Phase 3
- BevacizumabRoche · Phase 3
- CadonilimabAkeso · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Terminated | 9 Feb 2023 | Study of ADG106 In Combination With PD-1 Antibody In Advanced or Metastatic Solid Tumors and/or Non Hodgkin Lymphoma | |
| Phase 1Completed | 1 Nov 2021 | Study of ADG106 With Advanced or Metastatic Solid Tumors and/or Non-Hodgkin Lymphoma | |
| Phase 1Completed | 24 Jan 2022 | Study of CD137 Agonist ADG106 With Advanced or Metastatic Solid Tumors and/or Non-Hodgkin Lymphoma | |
| Phase 1Completed | 17 Jan 2024 | A Phase 1b/2 Study of ADG116, ADG116 Combined With Anti-PD-1 Antibody or Anti-CD137 Antibody in Solid Tumors Patients |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026